Adalimumab for the treatment of inflammatory bowel disease

References

• Loftus CG, Loftus EV Jr, Harmsen WS et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm. Bowel Dis.13(3), 254–261 (2007).
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology121(2), 255–260 (2001).
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet371(9613), 660–667 (2008).
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol.106(4), 590–599 (2010).
   Google Scholar
• Ford AC, Kane SV, Khan KJ et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am. J. Gastroenterol.106(4), 617–629 (2010).
   Google Scholar
• Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.6, CD000545 (2010).
   Google Scholar
• Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol.106(4), 630–642 (2011).
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumor necrosis factor α in stool as a marker of intestinal inflammation. Lancet339(8785), 89–91 (1992).
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology119(4), 1148–1157 (2000).
   PubMed Web of Science ®Google Scholar
• D’Haens G. Anti-TNF treatment in Crohn’s disease: toward tailored therapy? Am. J. Gastroenterol.105(5), 1140–1141 (2010).
   PubMedGoogle Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med.357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Panaccione R, Higgins PD et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am. J. Gastroenterol.106(2), 199–212 (2011).
   PubMed Web of Science ®Google Scholar
• Hesterberg PE, Winsor-Hines D, Briskin MJ et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α 4 β7. Gastroenterology111(5), 1373–1380 (1996).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology117(4), 761–769 (1999).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol.98(6), 1315–1324 (2003).
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med.348(7), 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology124(4), 917–924 (2003).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin. Gastroenterol. Hepatol.2(7), 542–553 (2004).
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.117(2), 244–279 (2008).
   PubMed Web of Science ®Google Scholar
• Humira injection, package insert. Abbott Laboratories, Chicago, IL, USA (2011).
   Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56(9), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial. Am. J. Gastroenterol.104(5), 1170–1179 (2009).
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Sandborn WJ et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment. Pharmacol. Ther.31(12), 1296–1309 (2010).
   PubMed Web of Science ®Google Scholar
• Lofberg R, Louis EV, Reinisch W et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: Results from CARE. Inflamm. Bowel Dis. DOI: 10.1002/ibd.21663 (2011) (Epub ahead of print).
   Google Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am. J. Gastroenterol.106(4), 674–684 (2011).
   PubMed Web of Science ®Google Scholar
• Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann. Intern. Med.135(10), 906–918 (2001).
   PubMedGoogle Scholar
• Lapidus A, Bernell O, Hellers G, Lofberg R. Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology114(6), 1151–1160 (1998).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Schwartz DA, Sandborn WJ et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut58(7), 940–948 (2009).
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Binion DG, Wolf DC et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment. Pharmacol. Ther.32(10), 1228–1239 (2010).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med.146(12), 829–838 (2007).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panaccione R, Sandborn WJ et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology135(5), 1493–1499 (2008).
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut60(6), 780–787 (2011).
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Kumar A, Pollack P, Lazar A, Thakkar RB. 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Gut60, A139–A140 (2011).
   Web of Science ®Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W et al. Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis. J. Crohns Colitis5(1), S12 (2011).
   Google Scholar
• Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane review. Cochrane Database Syst. Rev.16(2), CD008794 (2011).
   Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol.9(1), 36–41 (2011).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am. J. Gastroenterol.99(10), 1984–1989 (2004).
   PubMed Web of Science ®Google Scholar
• Billioud V, Laharie D, Filippi J et al. Adherence to adalimumab therapy in Crohn’s disease: a French multicenter experience. Inflamm. Bowel Dis.17(1), 152–159 (2011).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Thakkar RB, Lomax KG et al. Crohn’s disease mucosal healing in adalimumab-treated patients is affected by disease duration: results from EXTEND. Gastroenterology138(5), S164 (2010).
   Google Scholar
• Van Assche G, Ballet VS, Noman M et al. Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab. The prospective randomized Switch study. Gastroenterology138(5), S85 (2010).
   Google Scholar
• Sussman D, Chao J, Mulani P et al. Comparison of medical costs among patients using adalimumab or infliximab: a retrospective study. Am. J. Gastroenterol.105, S436 (2010).
   Google Scholar
• Columbel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med.362(15), 1383–1395 (2010).
   PubMedGoogle Scholar